First diagnostic solution at the point of care to serve as a digital platform connecting developers of digital health software and applications to healthcare professionals Basel, 12 January 2022 - ...
The cobas® c 703 and cobas® ISE neo analytical units, deliver higher testing capacity and increased automation helping to improve laboratory workflows and advance patient care. The new cobas c 703 ...
The new test detects up to 250 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis, and RSV, in a single patient sample. Rapid results enable doctors to make fast, confident ...
Infectious diseases, such as those infections transmitted via respiratory, sexually and transplant, are becoming increasingly difficult to manage and represent an ever-growing medical need for ...
INDIANAPOLIS, Oct. 29 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. introduction of the cobas e 602 analyzer, the latest addition to the cobas® 8000 modular analyzer ...
Hosted on MSN
Roche receives FDA clearance for cobas BV/CV assay, expanding women’s health diagnostics
The new molecular test broadens Roche’s sexual-health diagnostics portfolio by enabling simultaneous detection of bacterial vaginosis and Candida vaginitis from a single sample. ・Roche (USOTC:RHHBY) ...
Roche announced the launch of the cobas pulse system in select countries accepting the CE Mark. The cobas pulse system marks Roche Diagnostics’ newest generation of connected point of care solutions ...
Roche announced the launch of its new analytical units, cobas c 703 and cobas ISE neo, for the cobas pro integrated solutions, in countries accepting the CE mark. The cobas pro integrated solutions is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results